139 - Scientific Plenary
Health-related quality of life associated with every-3-week paclitaxel vs dose-dense weekly paclitaxel in combination with carboplatin with or without bevacizumab for primary ovarian cancer: Gynecologic Oncology Group study 262
Tuesday, March 25, 2014: 8:13 AM
Ballroom B/C (Tampa Convention Center)
B. J. Monk1, H. Huang2, R. T. Penson3, S. A. Davidson4, M. L. Pearl5, D. M. O'Malley6, D. P. Bender7, M. P. Boente8, L. P. Martin9, J. K. Chan10, J. L. Walker11 and C. K. McCourt12
1University of Arizona Cancer Center, Phoenix, AZ, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3Massachusetts General Hospital/Harvard University, Boston, MA, 4University of Colorado Denver, Aurora, CO, 5Stony Brook University Hospital, Stony Brook, NY, 6The Ohio State University, Columbus Cancer Council, Hilliard, OH, 7University of Iowa Hospitals and Clinics, Iowa City, IA, 8Minnesota Oncology Hematology PA, US Oncology, Edina, MN, 9Fox Chase Cancer Center, Philadelphia, PA, 10UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, 11The University of Oklahoma, Oklahoma City, OK, 12Women & Infants Hospital, Brown University, Providence, RI
